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Independent of Its Cholesterol-Lowering Actions
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Augusta, Georgia
Objectives. We tested the hypothesis that pravastatin (PRA)
activates endothelial nitric oxide synthase (eNOS).
Background. Pravastatin has been found to have clinical ben-
efits beyond those predicted by its actions in reducing plasma low
density lipoprotein cholesterol (LDL). Both PRA and simvastatin
(SIM) are equally effective in reducing LDL, but only PRA reduces
platelet aggregation and is an effective vasodilator. Nitric oxide
(NO) also inhibits platelet aggregation and vasodilates.
Methods. We determined PRA and SIM effects on vasorelax-
ation in aortic rings and NO production by cultured bovine aortic
endothelial cells. Nitric oxide was measured by using a NO
electrode and by an assay for conversion of hemoglobin to
methemoglobin. Specificity of NOS activation was tested by using
the NOS inhibitor nitro-L-arginine methyl ester (L-NAME, 1
mmol/liter) in the presence or absence of excess L-arginine
(L-ARG, 1 mmol/liter).
Results. Endothelium-dependent vasorelaxation was maximal
with acetylocholine (ACH, 100%), followed by PRA (62.8%) and
then SIM (37.1%). Direct measurement of NO confirmed that
vasorelaxation is due to NO release and showed that PRA and
ACH had similar dose-dependent effects on NO production, while
SIM was only 25% to 30% as effective. Methemoglobin assay
confirmed these results and demonstrated their specificity for
NOS activity. The L-NAME blunted the responses to 45% of initial
values. Excess L-ARG reversed this effect and potentiated NO
production to 133% of initial levels.
Conclusions. Both PRA and SIM activate eNOS, but SIM is
much less effective. Clinical benefits with PRA not explained by
LDL reductions may be the result of an independent action of
PRA on eNOS activation.
(J Am Coll Cardiol 1999;33:234–41)
©1998 by the American College of Cardiology
Clinical trials with pravastatin (PRA) have demonstrated
reductions in myocardial infarction (MI) and stroke beyond
those predicted by reductions in low density lipoprotein cho-
lesterol (LDL) (1). Similar benefits were seen in patients
without hypercholesterolemia following MI (2). Thirty-two
patients with stable coronary disease treated with PRA and
simvastatin (SIM) had comparable reductions in LDL, but
inhibition of platelet thrombosis was seen to a much greater
extent in the group receiving PRA (3). Studies in cynomologus
monkeys fed atherosclerotic diets revealed that the arteries of
the PRA-treated group had better vasodilator function and
plaque characteristics more consistent with stability than did
those of monkeys not receiving PRA. The beneficial effects of
PRA were independent of changes in LDL (4). Finally,
hypertensive Dahl salt-sensitive rats receiving PRA had blood
pressure reductions and renal protection by an unknown
mechanism that is unrelated to changes in LDL (5).
Pravastatin differs from SIM and the other statins as a result
of its open lactone ring chemical structure. When administered
as the active acid, its unbound plasma concentration available
for distribution to the peripheral circulation is approximately
100 times greater than that of the open-ring form of SIM (6).
Other studies have established that less than 5% of an oral
dose of SIM reaches the systemic circulation as the open
hydroxy-acid form (6). Therefore, PRA unlike SIM and the
other statins has the potential to interact with the endothelium
in a unique manner and this may, in part, be involved in the
benefits seen with PRA that are beyond those predicted by
LDL reductions.
Nitric oxide (NO) is a vasodilator and potent inhibitor of
platelet aggregation with actions on the IIb-IIIa receptor (7).
Some drugs [angiotensin-converting enzyme inhibitors (8),
amrinone (9), amlodipine (10), nebivolol (11), s-nitrosylated
tissue type plasminogen activator (12) estrogen (13), heparin
(14) and insulin (15)] possess an auxiliary mechanism of
activating endothelial nitric oxide synthase (eNOS). The pur-
pose of our study was to test the hypothesis that the unex-
plained clinical benefits and actions of PRA result principally
from an auxiliary mechanism of eNOS activation.
Materials and Methods
Drugs and chemicals. The following materials were used:
nitro L-arginine methyl ester (L-NAME), Earle’s balanced salt
solution, acetylcholine chloride (ACH), oxyhemoglobin, pep-
From the *Department of Pharmacology and Toxicology and the †Vascular
Biology Center, Medical College of Georgia, Augusta, Georgia 30912.
Manuscript received September 18, 1997; revised manuscript received
August 17, 1998, accepted September 17, 1998.
Address for correspondence: Dr. W. H. Kaesemeyer, Department of Phar-
macology and Toxicology, Medical College of Georgia, Augusta, Georgia 30912.
E-mail: wcaldwel@mail.mcg.edu.
JACC Vol. 33, No. 1
January 1999:234–41
234
©1998 by the American College of Cardiology 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(98)00514-2
statin A, leupeptin, bestatin, phenylsulphonylfluoride, and
L-arginine (L-ARG). All were purchased from Sigma Chemical
Co. (St. Louis, Missouri). Pravastatin (PRA) and simvastatin
(SIM) were of pharmaceutical grade.
Both PRA and ACH were dissolved in cell medium or
Kreb’s solution. Simvastatin was prepared in two forms. The
native, closed-lactone ring form is sparingly soluble in water.
Thus, it was dissolved in dimethyl sulfoxide (DMSO, 0.2% as
stock). To open the lactone ring, 4.2 mg of SIM was dissolved
in 0.1 ml of 95% ethanol and then 0.15 ml of 0.1 N NaOH was
added. After heating at 50°C for 2 h, the resulting solution was
neutralized with HCl to a pH of approximately 7.2 and brought
up to a volume of 1 ml with distilled water. Stock solutions
(1 mol/liter) were stored frozen.
Measurement of Vascular Tone
Male Sprague-Dawley rats were killed by decapitation. The
thoracic aorta was rapidly removed, cleaned from the adjacent
tissue and cut into four rings of approximately 4 mm in length.
Two metal hooks were carefully passed through the lumen of
each ring and then mounted in 25-ml organ baths containing
Kreb’s solution under 2 g of tension. Kreb’s solution had the
following composition (1 mmol/liter): NaCl, 118; KCl, 4.75;
CaCl2, 2.54; MgSO4z7H2O, 1.2; KH2PO4, 1.19; NaHCO3, 23;
Dextrose, 11; the pH of the solution was 7.35;7.45. Rings were
equilibrated for 90 min with solution changes every 15 min.
The bathing solution was kept at 37°C and was continuously
aerated with a mixture of 5% CO2 and 95% O2.
After equilibrium was established, l-phenylephrine, PE
(0.3 mmol/liter) was added to the organ bath and maximal
contraction developed. Increasing concentrations of either
acetylcholine (ACH), pravastatin (PRA) or simvastatin (SIM,
open ring) from 1 nmol/liter to 10 mmol/liter, were added to
the organ baths every 10 min and the degree of relaxation was
monitored. Cumulative dose response curves (DRC) were
constructed to ACH, PRA and SIM control over a period of 1
to 1.5 h. The bathing solution was drained and replaced with
fresh solution. The rings were allowed to return to the baseline
and another DRC was built using the same process as de-
scribed above. When SIM in its native closed-ring form was
examined (1 to 10 mmol/liter), control responses to DMSO
(0.001 to 0.00001%) were obtained. All responses were ex-
pressed as a percentage of the maximal relaxation. In other
experiments, the endothelium of the vascular rings were
removed by gently rolling of the luminal surface of the rings
over a small metal rod after its insertion into the vascular
lumen.
Measurement of Nitric Oxide Production by Bovine
Aortic Endothelial Cells
NO electrode method. Nitric oxide production was mea-
sured with a NO meter (MARK II ISO-NO, World Precision
Instruments, Sarasota, Florida) connected to a polargraphic
NO electrode as previously described (16). Bovine aortic
endothelial cells (BAECs) were obtained from Cell Systems
(Kirkland, Washington) and expanded in 150-mm plates
(Corning) to passages 4-6. The growth medium, medium-199,
was supplemented with penicillin G (100 U ml21), streptomy-
cin (100 mg ml21), glutamine (100 mg ml21), thymidine
(100 mg ml21) and 10% fetal calf serum (Gibco). For experi-
ments, BAECs were grown to confluence on 24-well plates.
Before NO measurement, the cells were washed twice with
phosphate buffered saline (PBS) and then bathed in fresh
medium-199. The NO sensor probe was next inserted vertically
into the wells such that the tip of the electrode was submerged
2 mm under the surface of the medium. The electrode was
routinely calibrated with graded concentrations of S-Nitroso-
N-acetyl-DL-penicillamine (SNAP), which produces [NO]
from 2 to 250 nmol/liter to obtain a standard curve.
The wells containing the confluent BAECs were randomly
divided into three treatment groups: 1) ACH, PRA or SIM (0.1
to 10 mmol/liter); 2) ACH, PRA or SIM (1 mmol/liter) after
pretreatment with the NOS inhibitor L-NAME (1 mmol/liter,
30 min); 3) SIM (1 to 10 mmol/liter) in the closed lactone ring
form. The peak reading of the meter represented the amount
of NO measured. The reaction was initiated when agents in
volumes of 10 ml were added to achieve the desired concen-
tration. Basal levels of NO varied between 46 and 67 nmol/liter
(mean: 57 nmol/liter). Values for basal NO were subtracted
from any drug-induced responses to determine NO production
resulting solely from the action of each drug.
Methemoglobin method. The effects of acetylcholine and
pravastatin on NO production in BAECs were determined
using a highly sensitive photometric assay for conversion of
oxyhemoglobin to methemoglobin. Nitric oxide oxidizes oxy-
hemoglobin (HbO2) to methemoglobin (metHb) in the follow-
ing reaction: HbO2 1 NO3 metHb 1 NO
23. Therefore, the
amount of NO produced by endothelial cells can be quantified
by measuring the change in absorbency as HbO2 oxidizes to
metHb. Oxyhemoglobin has an absorbency peak at 415 nm,
whereas metHb has a 406-nm absorbency peak. By subtracting
the absorbency of metHb from HbO2, the concentration of NO
can be assessed. Our general method was patterned after that
of Feelisch and Kelm (17) (see Fig. 1).
For these experiments BAECs were prepared on microcar-
rier beads (Cytodex #3, 1027 cells/0.5 g beads). After plating,
Abbreviations and Acronyms
ACH 5 acetylcholine
BAECs 5 bovine aortic endothelial cells
eNOS 5 endothelial nitric oxide synthase
L-ARG 5 L-arginine
LDL 5 LDL cholesterol
L-NAME 5 nitro-L-arginine methyl ester
MetHb 5 methemoglobin
NO 5 nitric oxide
PRA 5 pravastatin
SIM 5 simvastatin
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cells, beads and medium were transferred to a spinner flask
(Wheaton), which was incubated at 37°C with 95% O2 and 5%
CO2. The culture was left undisturbed for 29 min and spun
(20 rpm) in the same environment for 1 min. These resting and
spinning cycles were then repeated for 4 h. This sitting cycle
allowed for cell adherence to the beads while the spinning
created an even distribution of cells and beads. At the end of
this attachment phase, the spinner flask was left on the stirrer
at slow speed for 2 to 3 days to allow for uniform cellular
coating of beads.
For experiments, beads with cells were rinsed twice with
PBS and then suspended in a Hepes-buffered Krebs-Ringer
solution containing all necessary co-factors. To prevent a
reaction between NO and superoxide (O2
z2), superoxide dis-
mutase (200 U/ml) was added to the buffer. Catalase (100 U/ml)
was added to decompose hydrogen peroxidase, keeping the
hemoglobin active. Next, 2 ml of beads with cells were placed
into a water-jacketed chromatography column (Pharmacia
Biotech) and superfused at 2 ml/min with 3 mmol/liter oxyhe-
moglobin. The perfusate was then directed into a flow-through
cuvette in a dual-wavelength spectrophotometer, and absor-
bency was measured to determine the basal and stimulated NO
release. A parallel column circuit was filled with only beads (no
cells) to determine basal and spontaneous release of NO in the
system.
Experimental stimulation was carried out by 3-min infusion
periods of ACH or PRA added to buffer perfusion using a
microsyringe pump at a rate of 45 ml/min to yield a final
concentration of 1 and 10 mmol/liter for both ACH and PRA
in the buffer. Vehicle (buffer without agent) did not cause a
change in absorbency when infused into the cell/bead column.
The effects of buffer containing L-NAME (1 mmol/liter) in
blocking the actions of these drug agents and then a buffer
without L-NAME but with excess L-ARG (1 mmol/liter) in
reversing any L-NAME effect were also examined. Each drug
agent concentration was given twice for each of the three
buffer systems; a period of 10 min was allowed between
infusion of agents. Our data demonstrate that this cell perfu-
sion and monitoring system remains stable for at least 4 to 6 h.
At the end of each experiment, cell viability was checked using
trypan blue exclusion.
For analysis, we determined the area under the curve for
the change in absorbency response/min caused by each agent
above baseline levels. Production of MetHb was calculated
using an extinction coefficient of 39 mmol/liter21/cm21. During
the 3-min infusion of agents, absorbency increased rapidly.
Changes in absorbency to these agents usually persist from 2 to
8 min depending on the size of the response before returning
to baseline levels. We assume a one-to-one correspondence for
NO and metHb production, the known stoichiometric balance
for this reaction. We also determined levels in basal NO
production during perfusion with each of the buffer systems.
Basal levels of NO varied between 49 and 174 nmole/min
(mean: 105 nmole/min). Basal NO values were subtracted from
the drug-induced responses to determine NO production
resulting solely from the drug action.
Data analysis. The data are expressed as mean values 6
SEM. Data in Figures 2, 3A and 4A are absolute values for
experimental determinations. Data in Figures 3B and 4B are
expressed as a percentage of control responses in Figures 3A
and 4A, respectively. One-way analysis of variance was used to
determine whether differences exist among treatment groups.
The Newman-Kuels post hoc test was also employed. A
probability value of less than 0.05 was considered statistically
significant.
Results
Vascular tone. To test whether PRA could have an effect
on endothelial cell function independent of its lipid lowering
actions, we first compared the PRA and SIM vasorelaxing
actions with those of ACH using a model that has been well
established for demonstrating agents’ effects on endothelium-
dependent vasorelaxation. Acetylcholine, PRA and SIM all
produced relaxation of isolated aortic rings but exhibited
different potencies (Fig. 2). The maximum vasorelaxations to
ACH, PRA and SIM occurred at 10 mmol/liter and were 100 6
0%, 62.8 6 5.6% and 37.1 6 5.8%, respectively. Relaxation
responses to PRA and SIM occurred with the same latency,
;8 min. Responses to ACH occurred more rapidly, 1.5 to
2 min. Removal of the endothelium from the aorta completely
prevented relaxation responses to both PRA and ACH. Sim-
vastatin in the close lactone ring form did not affect vascular
tone.
Nitric oxide production. To determine and directly com-
pare the actions of ACH, PRA and SIM in stimulating NOS
activity and NO release, production of NO was assayed in
cultured BAECs using the NO-sensitive electrometer. To
further confirm the effects of PRA on endothelial cell NOS
activity and NO formation and to test the reversibility of the
Figure 1. Diagram illustrating methods used to measure NO produc-
tion. The upper left half of the figure illustrates the methemoglobin
method for measuring NO production in endothelial cells. The bottom
half of the figure illustrates the NO electrode method for measuring
NO production in endothelial cells.
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L-NAME effects in blocking BAEC responses to PRA, we used
the methemoglobin (MetHg) method for assaying NO release.
NO electrode method. Acetylcholine, PRA and SIM (0.1 to
10 mmol/liter) stimulated NOS activity and NO release (Figs. 3,
A and B). Responses were complete within 10 min. Both ACH
and PRA at 10 mmol/liter stimulated release of NO to similar
peak responses above basal levels—88 and 103 nmol/liter,
respectively—in cells with 50 mmol/liter L-ARG in media.
Lower concentrations of these agents produced smaller incre-
ments in NO production. Moreover, SIM stimulated NO
release, but the effects were weak with a peak response of 34
nmol/liter. The effects of 0.1 and 1 mmol/liter SIM were similar
to those of 10 mmol/liter, suggesting that the peak effect was
reached at the lower concentration. The native, closed-ring
form of SIM produced similar NO responses above basal levels
of 24.4 6 1.7, 26.7 6 1.4 and 26.0 6 1.3 nmol/liter at
concentrations of 0.1, 1 and 10 mmol/liter, respectively.
Pretreatment of cells with L-NAME (1 mmol/liter) blunted
the NO responses to 10 mmol/liter ACH, PRA and SIM
(open-ring form) to 18, 41 and 70% of control values, respec-
tively (Fig. 3B).
MetHb method. These experiments confirmed a
concentration-dependent effect of both ACH and PRA on
BAEC production of NO (Fig. 4A and B). The BAEC treated
with 1 and 10 mmol/liter ACH in the presence of 10 mmol/liter
L-ARG) increased their NO release from 227 to 521 nmol/min.
Cells treated with 1 and 10 mmol/liter PRA increased their NO
release from 185 to 413 nmole/min. Nitric oxide production
with both agents was seen within the first 30 s. The L-NAME
(1 mmol/liter) reduced ACH responses to 51% and 60% of
control values, whereas responses to PRA were reduced to
45% and 43% of control values. Addition of extra L-ARG
(1 mmol/liter) to the media reversed the action of L-NAME
and potentiated NO production in response to ACH and PRA
to 166% and 180% versus 168% and 154% of control values,
respectively.
Discussion
Summary. Paravastatin (PRA) stimulated vasorelaxation
responses in aortic rings. Removal of the endothelium from
aorta strips obliterated vasorelaxations produced, indicating
the endothelial cell-dependency of the response. Also, PRA
stimulated increases in NO production by cultured endothelial
cells similar to the effects seen with ACH. This was demon-
strated by directly measuring NO production with a NO-
sensitive electrode and confirmed by measuring NO produc-
tion using a highly sensitive MetHb assay. The NO production
was inhibited by the NOS inhibitor L-NAME and reversible
upon the addition of excess L-arginine to the medium, demon-
strating specificity of the effect. Simvastatin was only 25% to
30% as effective as PRA in inducing vasorelaxation and NO
release. No vasorelaxation responses were observed with the
closed lactone ring form of SIM. In the open-ring form, SIM
was slightly more effective in stimulating NO production than
it was in the closed-ring form.
Rationale. This study was designed to determine the ability
of PRA and SIM to stimulate NO production by vascular
endothelial cells independent of their effects on hepatic cho-
lesterol metabolism and to correlate NO production with
vasorelaxation responses. It has been suggested that increased
plasma LDL inhibits active transport of L-ARG by endothelial
cells (18), uncoupling the L-ARG:eNOS pathway and leading
to superoxide anion production (19). Because both superoxide
anion and its reaction product with NO, peroxynitrite
(OONOz2), produce tissue injury (20), it is possible that an
indirect action of PRA, and other 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors, may be to
normalize endothelial function by protecting the active argi-
nine transporter from injury by LDL, thereby preventing the
formation of O2
z2 and OONOz2 (19,20). These adverse effects
of elevated LDL in increasing superoxide anion levels can be
inhibited or reversed by L-ARG treatment (19,21).
Figure 2. Vasorelaxation response of preconstricted
aortic rings to increasing concentrations of ACH, PRA
and SIM. Responses to ACH and PRA were obliter-
ated following removal of the endothelial cells. Re-
sponses to SIM were seen only with the open lactone
ring form (OR) of the compound (responses to SIM in
the closed lactone ring preparation (CR) were no
different from those produced by the DMSO vehicle
used to solubilize the compound). (*) Indicates differ-
ence from responses to all other agents or pretreat-
ment. p , 0.05.
237JACC Vol. 33, No. 1 KAESEMEYER ET AL.
January 1999:234–41 PRAVASTATIN ACTIVATES eNOS
In our study the use of isolated endothelial cells maintained
in culture precluded the influence of PRA’s actions in lowering
hepatic production of LDL. Thus, our data suggest that in
addition to the indirect effects of PRA in preserving eNOS
activity by preventing endothelial cell injury caused by excess
plasma LDL, PRA may have a direct action on endothelial
cells. We postulate a direct action of stimulating endothelial
cell NO production independent of effects on cholesterol
metabolism for several reasons.
First, the fact that PRA stimulates NO production by
cultured endothelial cells clearly rules out the contribution of
its well-established actions in reducing plasma LDL levels.
Moreover, the rapid time course of the endothelial cell re-
sponse to PRA similar to that seen with ACH, a known eNOS
agonist, makes it very unlikely that the increase in NO produc-
tion could be a result of PRA effects on cholesterol metabolism
in the cultured cells. Endothelial cell nitric oxide synthase
activity is known to decrease with elevation of membrane
cholesterol levels (19) and HMG-CoA reductase inhibitors
have been shown to inhibit cholesterol synthesis in cultured
endothelial cells (22,23). However, it is very unlikely that
significant alterations in endothelial cell plasma membrane
cholesterol could occur within minutes of PRA addition to the
cultures. For this reason, it is unlikely that PRA-induced
reductions in membrane cholesterol levels could contribute to
its acute actions in stimulating NO release. Furthermore,
studies of PRA in cultured endothelial cells have shown that
cellular uptake of this polar compound is limited and that its
ability to inhibit LDL synthesis is relatively limited compared
with other “vastatin” agents (23).
Finally, the fact that similar PRA effects on NO production
were observed in three different assay conditions (one done in
presence of serum-containing medium and two done in serum-
free buffer) indicates that the presence or absence of LDL in
the culture environment did not affect the results. This strongly
supports a mechanism independent of the PRA effects on
cholesterol metabolism.
Recently, SIM and lovastatin have been shown to upregu-
late eNOS gene expression over a period of hours (24).
However, increases in eNOS expression could not contribute
to the acute changes in NO production that occurred within
minutes in our study. Therefore, our results suggest an addi-
Figure 3. (A) NO electrode assay of effects of ACH,
PRA and SIM on NO release by cultured BAECs.
Confluent cultures were prepared in 24-well plates
and treated with 0.1 to 10 mmol/liter concentrations
of ACH, PRA and SIM (open lactone ring prepa-
ration). Open bars indicate basal NO release.
Shaded bars indicate responses to agents above
basal production. (*) Indicates difference from basal
release (control); (†) indicates difference from re-
sponse at 0.1 mmol/liter, p , 0.05. (B) NO electrode
assay of L-NAME effects on BAEC responses to 1
mmol/liter of ACH, PRA and SIM (open ring prep-
aration only) as a percent of control responses to
these agents (A). (*) Indicates difference from con-
trol responses for that agent and dose. p , 0.05.
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tional, independent mechanism for the beneficial effects of
PRA in treatment of cardiovascular disease processes.
Clinical implications. Production of endothelium-derived
nitric oxide may explain the previously reported beneficial
effects of PRA in inhibiting platelet thrombus formation (3)
and in reducing myocardial infarction (MI) and stroke beyond
the levels that could be accounted for by its effect in reducing
LDL cholesterol levels (1). Promotion of NO production may
also account for the reductions seen in recurrent MI, stroke,
need for bypass surgery, and coronary angioplasty in patients
without hypercholesterolemia (2). This action would also explain
the vasodilator actions of PRA recently reported (25). Further-
more, our data from cultured cells and from data in humans (26)
suggest that this mechanism may be amplified clinically by admin-
istering PRA in arginine-based delivery systems.
The results of our study and a recent study of hypertension
(27) underscore the importance of avoiding the use of surro-
gate end points (28) such as reductions in LDL or blood
pressure as the principal criteria for choosing drugs in the
treatment of cardiovascular diseases. Reinforcing this point is
the recent finding that another statin, atoravastatin, has an
auxiliary action of increasing fibrinogen (29). This may offset
its beneficial effect on LDL lowering. The effects of atoravas-
tatin on primary end points remain to be determined.
Differences in the efficacy of L-NAME in inhibiting NO
responses to PRA and SIM are not readily explained and
remain under investigation. Differences in vasorelaxation to
PRA and SIM can be explained by the differences in degree of
NO production by these two agents. Although ACH and PRA
were about equally effective in producing NO, ACH was a
more potent vasorelaxant than was PRA. We believe this is
because of ACH’s ability to produce vasorelaxation in rat aorta
through mechanisms other than NO release—that is,
endothelium-derived hyperpolarization factor (30). Character-
istics of the vasorelaxation to PRA are comparable to those we
have previously observed with substance P (31).
Figure 4. (A) Methemoglobin assay of ACH and
PRA effects on NO release from cultured bovine
aortic endothelial cells. BAECs (2 ml) grown on
microcarrier beads were perfused with oxyhemo-
globin (3 mmol/liter) buffer containing 50 mmol/
liter L-arginine at 2 ml/min and then stimulated
with acetylcholine and pravastatin (1 and 10 mmol/
liter, 3 min, n 5 7). Open bars indicate basal NO
release. Shaded bars indicate responses to agents
above basal production. (*) Indicates difference
from basal release (control); (†) indicates differ-
ence from response at 0.1 mmol/liter p , 0.05. (B)
Methemoglobin of BAEC responses to ACH and
PRA in the presence of L-NAME and excess
L-arginine as percent of control responses to these
agents. Bars depict NO formation using the buffer
above supplemented with L-NAME (1 mmol/liter,
dark bar) or L-arginine (1 mmol/liter, light bar)
stimulated with acetylcholine and pravastatin (1
and 10 mmol/liter, 3 min, n 5 7). (*) indicates
difference from control responses for that agent
and dose; (#) indicates difference from responses
with L-NAME and control response for that agent
and dose. p , 0.05.
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It should be noted that vasorelaxation responses to SIM
were seen only with the open lactone ring preparation and that
SIM in the open-ring form was only 25% to 30% as effective as
PRA in producing NO. Coupled with the fact that only 5% of
SIM circulates in the open-ring form (6), this could explain the
failure of SIM to inhibit platelet aggregation as has been found
with PRA (3). It would also explain the findings that clinical
benefits of SIM appear more directly related to the magnitude
of the change in LDL levels than those seen with PRA (32–34).
eNOS activation. An auxiliary mechanism of PRA as an
eNOS agonist apart from its principal therapeutic mechanism
is not unique to PRA. In addition to those agents previously
discussed (8–15), our data in isolated rat aortic rings and
bovine aortic endothelial cells as well as in humans suggest that
nitroglycerin (GTN) elevates cGMP levels and NO production
by an L-arginine-dependent and L-NAME-sensitive mechanism
in addition to its known action of elevating cGMP with NO
derived from thiol-dependent enzymatic denitration of GTN
(35–37).
The mechanism(s) by which PRA stimulates NO produc-
tion in the endothelial cells is not known. It may act upon a
specific cell membrane receptor to allow entry of extracellular
calcium activating eNOS or it might act on membrane compo-
nents rather nonspecifically to activate eNOS or enhance
exposure of the enzyme to L-ARG. Whatever the process, our
data demonstrate that PRA causes an immediate release of
NO from these cells.
Conclusions. Paravastatin acutely activates eNOS to a sim-
ilar extent as ACH. Simvastatin also activates eNOS but is
much less effective. Vasorelaxation responses to PRA were
comparably greater than those seen with SIM. Previously
observed clinical benefits unrelated to LDL reduction and
differences in platelet inhibition between PRA and SIM may
be the result of the greater effectiveness of PRA as a NOS
agonist.
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